You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

Filtered By:
80 Items
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Drugs Used:
vinCRIStine,
DOXOrubicin,
methotrexate,
dexamethasone,
asparaginase,
cyclophosphamide,
cytarabine,
thioguanine
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Curative
Drugs Used:
DOXOrubicin,
bleomycin,
vinBLAStine,
dacarbazine
... Show more tags
Quick Link(s):
Regimen Monograph
Nov 2017
Cancer Type: Breast     
Intent: Palliative
Drugs Used:
DOXOrubicin,
cyclophosphamide
... Show more tags
Quick Link(s):
Regimen Monograph
Jan 2018
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Docetaxel - FEC-D or AC-DOCE for Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Docetaxel - Neoadjuvant treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
... Show more tags
Drugs Used:
DOXOrubicin,
cyclophosphamide,
DOCEtaxel,
trastuzumab
... Show more tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2019
Cancer Type: Breast     
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
... Show more tags
Drugs Used:
DOXOrubicin,
cyclophosphamide,
PACLitaxel,
PERTuzumab (Unfunded),
trastuzumab
... Show more tags
Quick Link(s):
Regimen Monograph
New
Nov 2019
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
... Show more tags
Drugs Used:
DOXOrubicin,
cyclophosphamide,
PACLitaxel,
trastuzumab
... Show more tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2019
Cancer Type: Breast     
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
... Show more tags
Drugs Used:
DOXOrubicin,
cyclophosphamide,
PACLitaxel,
PERTuzumab (Unfunded),
trastuzumab
... Show more tags
Quick Link(s):
Regimen Monograph
New
Nov 2019
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
... Show more tags
Drugs Used:
DOXOrubicin,
cyclophosphamide,
PACLitaxel,
trastuzumab
... Show more tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2019
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
... Show more tags
Drugs Used:
DOXOrubicin,
cyclophosphamide,
PACLitaxel,
trastuzumab
... Show more tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Updated
Dec 2019
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
... Show more tags
Drugs Used:
DOXOrubicin,
cyclophosphamide,
trastuzumab
... Show more tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Updated
Dec 2019
Cancer Type: Lung     
Intent: Neoadjuvant, Adjuvant, Palliative
Drugs Used:
DOXOrubicin,
CISplatin,
vinCRIStine,
cyclophosphamide
... Show more tags
Quick Link(s):
Regimen Monograph
May 2019
Cancer Type: Hematologic, Lymphoma - Hodgkin     
Intent: Curative
Funding:
ODB - General Benefit
    procarbazine
ODB - General Benefit
    prednisone
... Show more tags
Drugs Used:
cyclophosphamide,
DOXOrubicin,
etoposide,
procarbazine,
prednisone,
vinCRIStine,
bleomycin,
filgrastim
... Show more tags
Quick Link(s):
Regimen Monograph
Jun 2019